Conference Coverage
Newer DMTs are more effective than injectable DMTs in pediatric MS
A retrospective study suggests that the safety and tolerability of newer disease-modifying therapies are the same in children as in adults.
Conference Coverage
Neutrophil granulocyte markers may distinguish between demyelinating diseases
Evaluating CSF for neutrophil granulocyte markers may help distinguish between MS, neuromyelitis optica spectrum disorders, and anti–myelin...
Conference Coverage
Bacteria may be associated with risk of MS relapse
A study of patients with pediatric-onset MS suggests that methanogenesis pathways may play a role in the risk of relapse.
Conference Coverage
COVID-19 risks are no higher in patients with multiple sclerosis
MS does not appear to be associated with higher risks of severe COVID-19 outcomes compared with the general population.
Conference Coverage
Women with MS may have increased subclinical disease activity during pregnancy
Serum levels of neurofilament light increase among women with MS during pregnancy and the postpartum period.
Conference Coverage
Lower rituximab doses may be as effective, safer in MS
Adverse effects – particularly frequency of infection – were increased in the high-dose group.
Conference Coverage
Prior autoimmunity does not predict adverse events of alemtuzumab
Rare but serious and possibly life-threatening autoimmune events that have recently been linked to the drug.
Conference Coverage
B-cell test predicts alemtuzumab autoimmunity in MS
A higher percentage of total B cells, and in particular plasmablasts, could be a very predictive biomarker for autoimmunity after alemtuzumab...
Conference Coverage
Researchers identify five cognitive phenotypes in MS
Clinical and imaging examinations suggest discrete profiles of cognitive dysfunction with distinct neuroanatomical foundations.
Conference Coverage
Masitinib impresses in nonactive progressive MS
The investigational drug has shown a positive result in slowing disability in patients with primary progressive and secondary progressive forms of...
Conference Coverage
Multiple sclerosis prodrome holds promise of earlier diagnosis
“There is now no doubt that there is an MS prodrome measurable by increased healthcare usage and lifestyle changes that are recognizable 5-10...
Conference Coverage
High plasma GFAP level predicts disability accumulation in secondary progressive MS
The GFAP level may be a stronger predictor in women and in patients with nonactive disease, compared with active disease.
Conference Coverage
App for MS aims to capture elusive signals of progression
Researchers in Switzerland argue for seeing MS as a continuum of disease that can progress with or without relapse. Their new smartphone-based app...
Conference Coverage
Satralizumab reduces risk of severe NMOSD relapse
The treatment also was linked to a lower likelihood of receiving acute relapse therapy, but the study’s sample size was low.
Conference Coverage
Cardiovascular risk factors linked to brain atrophy in MS
Even low levels of exposure to cardiovascular risk factors are important in MS and might affect brain atrophy—and therefore long-term disability—...
Conference Coverage
Lessons for patients with MS and COVID-19
Patients with MS and COVID-19 avoided disease reactivation with combined PCR-serology testing and continued MS therapies with good results.
Conference Coverage
Exposure to DMT may delay disability accumulation in primary progressive MS
Longer exposure to treatment is associated with a reduced risk of being restricted to a wheelchair in this patient population.
Conference Coverage
-
Newer DMTs are more effective than injectable DMTs in pediatric MS -
Neutrophil granulocyte markers may distinguish between demyelinating diseases -
-
COVID-19 risks are no higher in patients with multiple sclerosis -
Multimedia
Question 1 of 5